Imbria Pharmaceuticals: Imbria Pharmaceuticals is a clinical stage company developing novel cardiometabolic therapies designed to substantially improve the lives of patients with life-altering diseases. Their clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy in disorders where energetic impairment is a fundamental contributor, including cardiovascular disease and specific inborn errors in metabolism. Ninerafaxstat, their lead program, is currently in Phase 2 clinical development in three indications: Hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction. The pipeline also includes IMB-203, designed to address the energy deficiency in patients with rare inborn errors of mitochondrial metabolism.